EVALUATION OF ANTIVIRALS FOR HEPATITIS C VIRUS IN CHIMPANZEES

黑猩猩抗丙型肝炎病毒抗病毒药物的评价

• 批准号: 7349764
• 负责人: Robert E LANFORD
• 金额: $ 0.77万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349764
• 关键词: EVALUATION; ANTIVIRALS; HEPATITIS; VIRUS; CHIMPANZEES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Approximately 2% of the US population is chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease, including cirrhosis and liver cancer in approximately 20% of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. The development of improved antiviral strategies to treat HCV chronic infection is essential for the control of this disease. The objective of this study is to test a series of nucleoside analogues as antiviral inhibitors of HCV replication in chronically infected chimpanzees. The level of viral RNA in the serum will be measured by TaqMan RT-PCR, and the animals will be monitored for safety and improved liver dise

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。大约2%的美国人口慢性感染丙型肝炎病毒（HCV）。慢性丙型肝炎病毒感染导致严重的肝脏疾病，包括约20%的感染者的肝硬化和肝癌。目前的干扰素和利巴韦林治疗在大多数病例中不能导致病毒清除。开发改进的抗病毒策略来治疗HCV慢性感染对于控制这种疾病至关重要。本研究的目的是测试一系列核苷类似物作为慢性感染黑猩猩丙型肝炎病毒复制的抗病毒抑制剂。通过TaqMan RT-PCR检测血清中的病毒RNA水平，并监测动物的安全性和肝脏疾病的改善情况